Evidence map›Paper›PMID 30478527›Full record

ArticleTransgenic research2019

Establishment of a transgenic mouse to model ETV7 expressing human tumors.

Masashi Numata, R I Klein Geltink, Gerard C Grosveld

Open access · hybridAbstract read
In one paragraph

Article in Transgenic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Masashi NumataDaiichi Sankyo Co., Ltd 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo, 140-8710, Japan.
R I Klein GeltinkDepartment of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Gerard C GrosveldDepartment of Genetics, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. Gerard.Grosveld@stjude.org.ORCID http://orcid.org/0000-0002-6583-1265
Daiichi Sankyo (Germany) · DEMax Planck Institute of Immunobiology and Epigenetics · DESt. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

The ETS transcription factor ETV7 has been characterized as a hematopoietic oncoprotein, which requires cooperating mutations for its leukemogenic activity. Although the ETV7 gene is highly conserved among vertebrates, part of the rodents, including Mus musculus, deleted the Etv7 gene locus. Many human hematopoietic malignancies upregulate ETV7 expression but contrary to ETV7's role in oncogenesis, its physiological role in normal tissues is unknown. To determine the physiological function of ETV7 in vivo and determine its role in tumorigenesis in a mouse model, we have generated an ETV7 transgenic mouse that carries a single copy of human BAC DNA containing the ETV7 gene locus and its regulatory sequences. ETV7 heterozygous (ETV7Tg

Indexed as

AnimalsCarcinogenesisDisease Models, AnimalGene Expression Regulation, NeoplasticHeterozygoteHumansMiceMice, TransgenicMyeloid CellsNeoplasmsProto-Oncogene Proteins c-etsPTEN PhosphohydrolaseETV7 protein, humanProto-Oncogene Proteins c-etsPTEN PhosphohydrolasePten protein, mouseETS transcription factorETV7LeukemiaTransgenic mouseTumor mouse model

Identifiers

PMID30478527
PMCPMC6353817
OpenAlexW2902963941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.